ReviewBlood research2026

Checkpoint inhibitor-induced hematologic immune-related adverse events and their association with disease recurrence in hematolymphoid malignancies: a clinical perspective.

Chokri Ben Lamine et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.